SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

11276	Companies
250573	Keywords
179203	Articles
136405	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 12/11/2025 at 07:00, 10 months 24 days ago

Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares
Sanofi voit Qfitlia et Cablivi approuvés en Chine pour traiter les maladies rares, marquant une avancée significative avec des approbations récentes dans le domaine de l'hématologie

Chine Sanofi Maladies Rares Qfitlia Cablivi
BRIEF

published on 12/04/2025 at 11:05, 11 months ago

Sanofi Completes Acquisition of Vicebio

Respiratory Viruses Sanofi Acquisition Molecular Clamp Vicebio Vaccine Vaccine Pipeline
BRIEF

published on 12/04/2025 at 11:05, 11 months ago

Sanofi finalise l'acquisition de Vicebio

Acquisition De Sanofi Virus Respiratoires Vaccin Vicebio Pince Moléculaire Pipeline Des Vaccins
PRESS RELEASE

published on 12/04/2025 at 11:00, 11 months ago

Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
Sanofi finalise l’acquisition de Vicebio et renforce son pipeline de vaccins respiratoires avec un candidat-vaccin innovant contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (HMPV)

Acquisition Sanofi Vaccin Vicebio Respiratoire
PRESS RELEASE

published on 12/04/2025 at 11:00, 11 months ago

Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio, enhancing its vaccine portfolio with a combination vaccine candidate for RSV and HMPV. The 'Molecular Clamp' technology expands vaccine design capabilities

Acquisition Sanofi Vaccine Candidate RSV Vicebio
BRIEF

published on 11/25/2025 at 07:05, 11 months 9 days ago

Dupixent : une avancée dans le traitement de l'urticaire chronique spontanée en Europe

Sanofi Dupixent Regeneron Traitement Innovant Urticaire Chronique
BRIEF

published on 11/25/2025 at 07:05, 11 months 9 days ago

Dupixent: a breakthrough in the treatment of chronic spontaneous urticaria in Europe

Innovative Treatment Sanofi Dupixent Regeneron Chronic Urticaria
PRESS RELEASE

published on 11/25/2025 at 07:00, 11 months 9 days ago

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée
Dupixent de Sanofi et Regeneron approuvé dans l'UE pour l'urticaire chronique spontanée. Impact positif sur les patients avec symptômes malgré antihistaminiques. Nouvelle option thérapeutique basée sur inhibition IL4 et IL13

Traitement Sanofi Dupixent Regeneron Urticaire
PRESS RELEASE

published on 11/25/2025 at 07:00, 11 months 9 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron receive EU approval for Dupixent as targeted medicine for chronic spontaneous urticaria, significantly reducing itch and hives compared to placebo

Sanofi Dupixent EU Approval Regeneron Chronic Spontaneous Urticaria
PRESS RELEASE

published on 11/17/2025 at 18:15, 11 months 17 days ago

Sanofi : Déclaration des transactions sur actions propres

Accesswire

Published on 11/04/2026 at 15:55, 5 hours 2 minutes ago

Boba Mint Outlines Planned Heatcheck Rebrand and Asset Restructuring and Announces Cease Trade Order
Published on 11/04/2026 at 15:07, 5 hours 50 minutes ago

Boron One Signs Second Binding Offtake Agreement for Sale of Boron Concentrates and Refined Boron Products
Published on 11/04/2026 at 15:00, 5 hours 57 minutes ago

Vox Royalty Provides Update & Timeline for Assets Entering Production
Published on 11/04/2026 at 15:00, 5 hours 57 minutes ago

ShelfieTech Announces Closing of Acquisition of Majority Interest in Aspect
Published on 11/04/2026 at 14:00, 6 hours 57 minutes ago

Adcore to Publish Third Quarter 2026 Results on November 10, 2026

View all ACCESSWIRE

EQS Group

Published on 11/04/2026 at 19:41, 1 hour 16 minutes ago

EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 1 hour 32 minutes ago

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 2 hours 14 minutes ago

EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 2 hours 52 minutes ago

Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 17:40, 3 hours 17 minutes ago

Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.26.

Les Echos

Published on 11/04/2026 at 18:00, 2 hours 57 minutes ago

The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 2 hours 57 minutes ago

L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:45, 3 hours 12 minutes ago

October 2026
Published on 11/04/2026 at 17:45, 3 hours 12 minutes ago

Octobre 2026
Published on 11/04/2026 at 17:44, 3 hours 13 minutes ago

Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026

View all LES ECHOS COMFI WIRE